Novel anticancer therapies are changing the landscape of clinical oncology and nephrology practice. With improved survival rates, many cancer survivors are developing kidney disease as a result of their cancer treatment. As a consequence, a new medical sub-specialty has emerged, termed “onco-nephrology.” Onco-nephrology is a broad term encompassing acute and chronic kidney disease from cancer therapy as well as other effects, such as hypertension and electrolyte disturbances. For the practicing nephrologist, it is important to be aware of emerging toxicities from relatively newer anticancer therapies. In this review, we provide an update on the renal toxicity of emerging anticancer therapies, including immune checkpoint inhibitors, angiogenesis inhibitors, and BRAF inhibitors.
CortazarFBMarroneKATroxellML. Clinicopathological features of AKI associated with immune checkpoint inhibitors. Kidney Int2016903638–647
2.
PerazellaMACheckmate: kidney injury associated with targeted cancer immunotherapy. Kidney Int2016903474–476
3.
PostowMACallahanMKWolchokJDImmune Checkpoint Blockade in Cancer Therapy. J Clin Oncol201533171974–1982
4.
RobertCLongGVBradyB. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med20153724320–330
5.
RobertCSchachterJLongGVet al;KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med2015372262521–2532
6.
LarkinJChiarion-SileniVGonzalezR. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med2015373123–34
7.
BorghaeiHPaz-AresLHornL. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med2015373171627–1639
8.
BrahmerJRTykodiSSChowLQ. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med2012366262455–2465
9.
MichotJMBigenwaldCChampiatS. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer201654139–148
10.
SpainLDiemSLarkinJManagement of toxicities of immune checkpoint inhibitors. Cancer Treat Rev20164451–60
11.
ChmielKDSuanDLiddleC. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol2011299e237–e240
12.
HodiFSODaySJMcDermottDF. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med20103638711–723
13.
LuteKDMayKFJrLuP. Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. Blood200510693127–3133
14.
FadelFEl KarouiKKnebelmannBAnti-CTLA4 antibody-induced lupus nephritis. N Engl J Med20093612211–212
15.
IzzedineHGueutinVGharbiC. Kidney injuries related to ipilimumab. Invest New Drugs2014324769–773
CalabròLMorraAFonsattiE. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med201534301–309
18.
FreemanGJLongAJIwaiY. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med200019271027–1034
KinseyGRSharmaRHuangL. Regulatory T cells suppress innate immunity in kidney ischemia-reperfusion injury. J Am Soc Nephrol20092081744–1753
21.
JaworskaKRatajczakJHuangL. Both PD-1 ligands protect the kidney from ischemia reperfusion injury. J Immunol20151941325–333
22.
NishimuraHNoseMHiaiHMinatoNHonjoTDevelopment of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity1999112141–151
23.
HofmannLForschnerALoquaiC. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer201660190–209
24.
ShiraliACPerazellaMAGettingerSAssociation of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. Am J Kidney Dis2016682287–291
25.
Abdel-RahmanOFouadMA network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors. Immunotherapy201685665–674
26.
LinJSchiffMSalvatoreSShoustariAGlezermanIMembranous Nephropathy Related to the Checkpoint Inhibitor Nivolumab. J Am Soc Nephrol201627102A
27.
KitshluAFingrutWAvila-CasadoCReichHNephrotic Syndrome with Cancer Immunotherapies. J Am Soc Nephrol201627374A
28.
RayAGhoshSGhoshMYarlagaddaSNivolumab Induced Renal Failure with Collapsing Focal Segmental Glomerulosclerosis (FSGS). J Am Soc Nephrol2016271010A
29.
BreenECVEGF in biological control. J Cell Biochem200710261358–1367
30.
MaynardSEMinJYMerchanJ. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest20031115649–658
31.
MaharajASSaint-GeniezMMaldonadoAED'AmorePAVascular endothelial growth factor localization in the adult. Am J Pathol20061682639–648
32.
EreminaVSoodMHaighJ. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest20031115707–716
33.
EreminaVJeffersonJAKowalewskaJ. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med2008358111129–1136
34.
YogiAOConnorSECalleraGETostesRCTouyzRMReceptor and nonreceptor tyrosine kinases in vascular biology of hypertension. Curr Opin Nephrol Hypertens2010192169–176
35.
ZhuXWuSDahutWLParikhCRRisks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis2007492186–193
36.
WuSKimCBaerLZhuXBevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol20102181381–1389
37.
den DeurwaarderESDesarIMSteenbergenEJMuldersPFWetzelsJFvan HerpenCMKidney injury during VEGF inhibitor therapy. Neth J Med2012706267–271
38.
UsuiJGlezermanIGSalvatoreSPChandranCBFlombaumCDSeshanSVClinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. Hum Pathol20144591918–1927
39.
JhaveriKDFlombaumCDKroogGGlezermanIGNephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature. Nephron Clin Pract20111174c312–c319
40.
VigneauCLorcyNDolley-HitzeT. All anti-vascular endothelial growth factor drugs can induce pre-eclampsia-like syndrome: a RARe study. Nephrol Dial Transplant2014292325–332
41.
IzzedineHEscudierBLhommeC. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine (Baltimore)20149324333–339
42.
IzzedineHIsnard-BagnisCLaunay-VacherV. Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant200621113038–3045
43.
DahlbergSESandlerABBrahmerJRSchillerJHJohnsonDHClinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol2010286949–954
44.
IzzedineHEderhySGoldwasserF. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol2009205807–815
45.
RiniBICohenDPLuDR. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst20111039763–773
46.
PatelTVMorganJADemetriGD. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst20081004282–284
47.
PengLZhaoQYeXZhouYHuDZhengSIncidence and risk of proteinuria with aflibercept in cancer patients: a meta-analysis. PLoS ONE2014911e111839
48.
LangenbergMHvan HerpenCMDe BonoJ. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. J Clin Oncol200927366152–6159
49.
OsumiHMatsusakaSWakatsukiTSuenagaMShinozakiEMizunumaNAngiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients. Molecular and clinical oncology2015361295–1300
50.
McKayRRRodriguezGELinX. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research201521112471–2479
51.
MaitlandMLBakrisGLBlackHRet al;Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst20101029596–604
52.
Regnier-RosencherELazarethHGressierLAvrilMFThervetEDupinNAKI in patients with severe rash on vemurafenib treatment for metastatic melanomas. Br J Dermatol20131694934–938
53.
Launay-VacherVZimner-RapuchSPoulalhonN. Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients. Cancer2014120142158–2163
54.
HagenBTrinhVAManaging Side Effects of Vemurafenib Therapy for Advanced Melanoma. J Adv Pract Oncol201456400–410
55.
TroxellMLHigginsJPKambhamNAntineoplastic Treatment and Renal Injury: An Update on Renal Pathology Due to Cytotoxic and Targeted Therapies. Adv Anat Pathol2016235310–329
56.
ChaibHHoskinsBEAshrafSGoyalMWigginsRCHildebrandtFIdentification of BRAF as a new interactor of PLCepsilon1, the protein mutated in nephrotic syndrome type 3. Am J Physiol Renal Physiol20082941F93–F99
57.
JhaveriKDSakhiyaVFishbaneSNephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib. JAMA Oncol2015181133–1134
Arastu-KapurSAnderlJLKrausM. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clinical cancer research: an official journal of the American Association for Cancer Research20111792734–2743
60.
SiegelDMartinTNookaA. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica201398111753–1761
61.
HarveyRDIncidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib. Clin Pharmacol2014687–96
62.
QaqishISchlamIMChakkeraHAFonsecaRAdamskiJCarfilzomib: A cause of drug associated thrombotic microangiopathy. Transfus Apheresis Sci2016543401–404
63.
YuiJCVan KeerJWeissBM. Proteasome inhibitor associated thrombotic microangiopathy. Am J Hematol2016919E348–E352
64.
GlezermanIGPietanzaMCMillerVSeshanSVKidney tubular toxicity of maintenance pemetrexed therapy. Am J Kidney Dis2011585817–820
65.
PerazellaMAIzzedineHNew drug toxicities in the onco-nephrology world. Kidney Int2015875909–917
66.
KurataTIwamotoTKawaharaYOkudaMCharacteristics of pemetrexed transport by renal basolateral organic anion transporter hOAT3. Drug Metab Pharmacokinet2014292148–153
67.
StavroulopoulosANakopoulouLXydakisAMArestiVNikolakopoulouAKlouvasGInterstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed. Ren Fail20103281000–1004
68.
VootukuruVLiewYPNallyJVJrPemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer. Med Oncol2006233419–422
69.
CastroMThymidine rescue: an antidote for pemetrexed-related toxicity in the setting of acute renal failure. J Clin Oncol200321214066
70.
BrosnanEMWeickhardtAJLuX. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer20141205664–674
71.
CamidgeDRBrosnanEMDeSilvaCKooPJChoncholMCrizotinib effects on creatinine and non-creatinine-based measures of glomerular filtration rate. J Thorac Oncol20149111634–1637
72.
GastaudLAmbrosettiDOttoJ. AKI following crizotinib administration for non-small-cell lung carcinoma. Lung Cancer2013822362–364
73.
SchnellPBartlettCHSolomonBJ. Complex renal cysts associated with crizotinib treatment. Cancer Med201546887–896
